Initiatives / FAST / Employer Precision Oncology Pilot
Employer Precision Oncology Pilot · ISP 2026004
Helping employers close the testing gap.
Within 12 months of activation, a participating Memphis employer will increase completion of guideline-concordant comprehensive genomic testing by at least 20% from baseline among eligible employees and covered dependents.
Why this program
The case for acting now.
Cancer is driving high-cost claims, yet only about 35% of eligible patients receive appropriate genomic testing.
Self-insured employers have a direct incentive to improve cancer outcomes and avoid unnecessary costs by removing barriers to appropriate testing.
Healthcare costs are projected to rise about 9% in 2027, increasing employer urgency to improve outcomes.
Sources: AccessHope and Lantern, The Cancer Attention Gap (2026); Business Group on Health, 2027 Employer Healthcare Strategy Survey.
Who it's for
The people this program serves.
Employees and covered dependents with cancers for which comprehensive genomic testing is recommended.
Priority indicators
In their words
- “As someone diagnosed with cancer, I want to understand whether genomic testing may be appropriate for me.
- “As someone eligible for testing, I want to know whether it's covered.
- “As someone who completes testing, I want my results available to inform my care.
The journey
Every step, from start to finish.
Each Implementation Support Program finds what works and scales it rapidly. Here is the path this one follows.
What it involves
Barriers in, support out.
- Limited benefit coverage
- Unclear testing eligibility
- Limited awareness of testing
- Prior authorization requirements
- Out-of-pocket costs
- Inconsistent access to testing
- Baseline assessment of testing, cost and coverage
- A testing access pathway co-created with the employer
- Clinical and economic impact modeling
- Navigation to appropriate testing
- Measurement against baseline
What we measure
Every step, measured.
Also measured
- Employer engagement
- Benefit assessment
- Informed benefit decisions
- Testing completion
- Implementation insights for regional and national scale
Timeline
12 months, from baseline to measured change.
Timing depends on partner alignment and on governance, protocol and IRB requirements.
Our commitments
Independent and non-promotional.
FAST is lab-agnostic and treatment-agnostic. Comprehensive genomic testing should be considered when clinically appropriate and recommended by guidelines, and clinical decisions stay with patients and their clinicians.
Implementation Support Programs are sponsored separately from AHIS campaigns, and every sponsor is named here once an agreement is signed. The program follows a defined protocol, run under AHIS governance and the MONARCH operating standard for implementation measurement. Sponsors may help identify implementation challenges, populations or outcomes of interest. Design, governance and evaluation stay independent. Sponsors receive aggregate, de-identified results only.
Overseen by the AHIS Board in Phase 1 of AHIS governance, and by the Implementation Advisory Committee from Phase 2. Impact reports are shared publicly, including what didn't work.
Get involved.
Assess your cancer benefit, or join as a coalition, clinical or testing partner.
